Back to News
Market Impact: 0.2
Guggenheim Initiates Coverage of LB Pharmaceuticals at Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 6, 2026, Guggenheim initiated coverage of LB Pharmaceuticals (NASDAQGM:LBRX) with a Buy recommendation. The article notes a Roth Capital downgrade on October 5, 2026, but the available text cuts off before specifying its details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
LBRX0.35
More News
- JPMorgan and Deutsche Bank just upgraded Brazilian stocks. How to trade them
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares
- Meta may ditch the idea of a cloud business for Muse. We think that’s a good trade
- Why is Telix Pharmaceuticals stock rallying today?
- A new analyst call on Home Depot reflects our feeling on what to do with the stock
- Why is Broadcom stock rallying today?